Allergan Plc (AGN)

138.75
0.79 0.57
NYSE : Health Technology
Prev Close 137.96
Open 137.90
Day Low/High 137.90 / 139.68
52 Wk Low/High 125.84 / 197.00
Volume 431.00K
Avg Volume 2.79M
Exchange NYSE
Shares Outstanding 337.29M
Market Cap 46.91B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (2.07%)
Allergan Responds To Public Shareholder Letter

Allergan Responds To Public Shareholder Letter

DUBLIN, Feb. 19, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today issued the following statement from its Board of Directors in response to a public shareholder letter: "While we appreciate the input of Appaloosa as we do all of our shareholders, we...

Robert J. Hugin Appointed To Allergan Board Of Directors

Robert J. Hugin Appointed To Allergan Board Of Directors

- Sixth New Director Since 2017 as Part of Allergan's Transformation from a Generic to a Branded Biopharmaceutical Company -

ALLERGAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ALLERGAN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

Allergan To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Allergan To Present At The 8th Annual SVB Leerink Global Healthcare Conference

DUBLIN, Feb. 15, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 8 th Annual SVB Leerink Global Healthcare...

Aegon Reports Second Half 2018 Results

Aegon Reports Second Half 2018 Results

Net income declines to EUR 253 million reflecting unfavorable market movements and other charges Underlying earnings decrease by 8% to EUR 1,010 million, as lower Retirement Plans earnings in the US more than offset business growth and higher margins in...

Aegon To Grow Capital Generation And Dividends

Aegon To Grow Capital Generation And Dividends

Aegon has set new medium-term financial targets with a focus on growing capital generation and dividends.

Evolus Stockholders May Be Frowning in the Short Run

Evolus Stockholders May Be Frowning in the Short Run

Shares of the Botox competitor could correct/consolidate after a recent surge.

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't get too bearish, says Jim Cramer, but don't break discipline here. This is a perfectly reasonable decline.

When Everyone Sees the Obvious the Obvious Rarely Happens

Right now it feels as though everyone sees the obvious resistance and overbought situation.

Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management

Botox Maker Allergan Falls After Tepper's Hedge Fund Challenges Management

Shares of Botox maker Allergan slipped after a billionaire hedge-fund manager challenges the company's management.

Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox

Allergan Slides, Evolus Gains as FDA Approves Wrinkle Treatment to Rival Botox

Evolus surges Monday after the U.S. Food and Drug Administration approves the company's new wrinkle treatment for adult patients which is expected to be a key rival to Allergan's Botox.

ALLERGAN SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ALLERGAN SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.

A Pharma Giant, an Airline and Other Stocks That Look Good Short

AGN, AVA, ALK, RLI and CRT all recently were downgraded by TheStreet's Quant Ratings.

How Are My Ideas Working Out? January Trade Review (Part 2)

How Are My Ideas Working Out? January Trade Review (Part 2)

Clearly, the first half of the month shaped up better than the second half.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALEX, CATS, EXTR, LAD Downgrades: AGN Initiations: LBC, MRBK, SBT Read on to get TheStreet Quant Ratings' detailed report:

What Boeing's Report Means for U.S. Companies With China Exposure

What Boeing's Report Means for U.S. Companies With China Exposure

Kate Warne, investment strategist at Edward Jones, talked to TheStreet about what Boeing's report means for U.S. companies with exposure to China, Apple's beat and how the healthcare sector is looking.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Allergan Plc. Of Class Action Lawsuit And Upcoming Deadline - AGN

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Allergan Plc. Of Class Action Lawsuit And Upcoming Deadline - AGN

NEW YORK, Jan. 29, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Allergan plc.

Allergan Tumbles After Swinging to Fourth-Quarter Loss

Allergan Tumbles After Swinging to Fourth-Quarter Loss

Botox maker reports a fourth-quarter loss of $4.3 billion, a reversal from a year-earlier profit of $3.05 billion.

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.

Allergan Reports Fourth Quarter And Full-Year 2018 Financial Results

Allergan Reports Fourth Quarter And Full-Year 2018 Financial Results

- Full-Year 2018 GAAP Net Revenues of $15.8 Billion; Q4 2018 GAAP Net Revenues of $4.1 Billion -

New BOTOX® Cosmetic (onabotulinumtoxinA) "Own Your Look" Campaign Brings Fresh Face To Trusted Brand

New BOTOX® Cosmetic (onabotulinumtoxinA) "Own Your Look" Campaign Brings Fresh Face To Trusted Brand

Campaign targets new generation of users with an updated, modern approach

Earnings Preview: Apple, AMD, Verizon, Other Giants to Report Crucial Q4

Earnings Preview: Apple, AMD, Verizon, Other Giants to Report Crucial Q4

Eight important companies report earnings between Monday and Tuesday. Don't miss them.

Allergan Could Retest Its December Low Before a Better Rally Attempt

Allergan Could Retest Its December Low Before a Better Rally Attempt

Allergan could move higher but some sort of retest of the December low seems in order in the short to intermediate term.

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

ALLERGAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ALLERGAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

NEW ORLEANS, Jan. 25, 2019 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.

Allergan Announces Increased Quarterly Dividend And Annual General Meeting Of Shareholders Date

Allergan Announces Increased Quarterly Dividend And Annual General Meeting Of Shareholders Date

- First Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share to be Paid on March 15, 2019; Record Date of February 15, 2019 -

Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab

Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab

Study Evaluated Pharmacokinetics, Efficacy and Safety of ABP 798 Compared to Rituximab in Patients With Moderate-to-Severe Rheumatoid Arthritis

Jim Cramer: What Are We to Make of Today's Market Decline?

Jim Cramer: What Are We to Make of Today's Market Decline?

Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?

TheStreet Quant Rating: D+ (Sell)